Dupixent Keeps Sanofi At Forefront Of European Pharma Growth
Hints At Raised Forecast For Blockbuster
Sanofi is on a roll thanks to Dupixent and the blockbuster is providing breathing space even when some key pipeline assets are delayed.
You may also be interested in...
The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.
The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.
The France-headquartered company has brought forward its carbon neutral goal, making it one of the sector’s most proactive companies.